

GRIFOLS

Thomas Glanzmann new Grifols Executive Chairman, after Steven F. Mayer resignation

- **Mr. Glanzmann, with more than 16 years serving as a Grifols board member and acting as Vice Chairman since 2017, will be the new Grifols Executive Chairperson, effective immediately**
- **The Grifols Board has accepted the resignation of Mr. Steven F. Mayer as Executive Chairman for health and other personal reasons**
- **With extensive professional expertise in the healthcare and financial sectors, Mr. Glanzmann is a devotee of innovation and sustainability, being Chairman of Grifols' Sustainability Committee since 2020**
- **Thomas Glanzmann will continue to drive the company's long-term strategy, implementing the recently announced operational improvement plan to its full extent to increase value for all shareholders and reducing debt levels**

Barcelona, Spain, February 21, 2023 - Today, the Board of Directors of Grifols announced the resignation of Steven F. Mayer as Executive Chairman, and the appointment of Thomas Glanzmann as the new Executive Chairperson of Grifols and its Board of Directors.

Mr. Mayer, who was appointed to the role on 30th of September 2022, has taken the decision to resign due to health and other personal reasons.

The Board of Directors appointed Mr. Mayer to accelerate the execution of the company's strategic plan. The designation of Mr. Glanzmann builds on this commitment to continue to drive the company's long-term strategy and increase value for all shareholders, with emphasis on the reduction of debt levels and cash generation.

Over the last months, the company initiated a comprehensive operational improvement plan to enhance organizational efficiency, strengthen financial performance, and to position the company for future growth. Mr. Glanzmann is committed to the execution of the plan to its full extent.

The Board of Directors accepted Mr. Mayer's resignation with great appreciation for his contribution and personal commitment over these past months.

Said Mr. Mayer, *"Grifols is a great company with strong values and an important mission. Being able to help shape an operational improvement plan and contribute to other aspects of the company's organization, business, and strategy has been a privilege. I am confident that the work that was done over the last months, and will continue into the future, will, in the long term, have a significant positive effect on the company and on its many patients, donors, employees, and other stakeholders. Unfortunately, due to health*

GRIFOLS

issues and other personal reasons I have decided to step aside at this time. I wish Grifols and the new Executive Chairperson, whom I've known well for many years, every success in the future."

Thomas Glanzmann, a Swiss national who has served as a director of Grifols since 2006 and as Grifols' Vice-Chair since January 2017, has been associated with the plasma industry for most of his professional career. He has held key roles as President of Baxter Bioscience, CEO of Immuno International, and President of the European Biotech group.

He will assume the Chairman's role from Steven F. Mayer, effective immediately.

According to the Board of Directors, *"We believe that the appointment of Mr. Glanzmann, with his strong international and operational background and deep understanding of the industry and the company will be key to successfully implementing the upcoming actions to drive the company to the next chapter of growth"*

Raimon Grifols Roura has been appointed to succeed Thomas Glanzmann as the Vice-Chair of Grifols' Board, a duty that he will combine with his current Co-CEO responsibility.

The Board of Directors has also approved the appointment of James Costos as member and Chairman of the Sustainability Committee, substituting Thomas Glanzmann in such position and the removal of Mr. Costos as member and Chairman of the Appointments and Remuneration Committee. Additionally, Carina Szpilka has been appointed as member and Chairperson of the Appointments and Remuneration Committee, a responsibility that she will combine with her current responsibilities as the Company's Lead Independent Director and member of the Audit Committee.

Mr. Mayer will not continue as a board member and the Board of Directors has expressed its gratitude for his services.

Thomas Glanzmann

Mr. Glanzmann has served as director of Grifols since April 2006 and has been Vice-Chairman of the Board since January 2017. He has led the Sustainability Committee since December 2020.

Thomas Glanzmann is the former CEO of Gambro and HemoCue AB. From 1988 to 2004 he held leading positions at Baxter Healthcare and Baxter International where, from 1998 to 2004, he served as Senior VP and President of Baxter Bioscience.

He has also been the CEO of Immuno International, a leading global plasma and vaccines company. He was a Managing Director at The World Economic Forum, and for 10 years he also served as a Healthcare Advisor for Madison Dearborn Partners, a Chicago based private equity company.

Currently, Mr. Glanzmann serves as a Board member of Alcon, Inc., where he chairs the Innovation Committee and is a member of the Compensation and Governance Committees. He is a Founding Partner of a San Francisco based MedTech Fund.

GRIFOLS

Thomas Glanzmann is a graduate of Dartmouth College and holds an MBA from IMD in Switzerland and a Board of Directors Certification from the UCLA Anderson School of Management.

INVESTORS:

Grifols Investors Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

MEDIA CONTACTS:

Grifols Press Office media@grifols.com Tel. +34 93 571 00 02	
Spain Duomo Comunicación Tel.: +34 91 311 92 89 – +34 91 311 92 90 Raquel Lumbreras (Tel. +34 659 572 185) Raquel_lumbreras@duomocomunicacion.com Borja Gómez (Tel. +34 650 402 225) Borja_gomez@duomocomunicacion.com	International Finsbury Glover Hering Email: Grifols-global@finsbury.com Tel.: +44 20 7251 3801

About Grifols

Grifols is a global healthcare company which was founded in Barcelona in 1909 and is committed to improving the health and well-being of people around the world. Its three main business units – Biopharma, Diagnostic and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 110 countries.

A pioneer in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 27,000 employees in more than 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2021, Grifols' economic impact in its core countries of operation was EUR 7.7 billion. The company also generated 141,500 jobs, including indirect and induced jobs.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Spanish Main Market (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com



LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.